Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 14;6(2):122-127.
doi: 10.1055/s-0038-1660790. eCollection 2018 Jun.

Osteoporosis: Current Concepts

Ibrahim Akkawi  1 , Hassan Zmerly  1
Affiliations
Review

Osteoporosis: Current Concepts

Ibrahim Akkawi et al. Joints. .

Abstract

Osteoporosis is a worldwide disease characterized by reduction of bone mass and alteration of bone architecture resulting in increased bone fragility and increased fracture risk. Causes of osteoporosis include increasing age, female sex, postmenopausal status, hypogonadism or premature ovarian failure, low body mass index, ethnic background, rheumatoid arthritis, low bone mineral density (BMD), vitamin D deficiency, low calcium intake, hyperkyphosis, current smoking, alcohol abuse, immobilization, and long-term use of certain medications. The diagnosis of osteoporosis is established by measurement of BMD of the hip and spine using dual energy X-ray absorptiometry. According to the World Health Organization criteria, osteoporosis is defined as a BMD that lies 2.5 standard deviation or more below the average value for young healthy women. Bone turnover biomarker detection may be useful in monitoring osteoporosis treatment and assessing fracture risk but not for diagnosis of osteoporosis. Management of osteoporosis consists of nonpharmacological interventions, which are recommended for all subjects, and pharmacological therapy in all postmenopausal women who have had an osteoporotic fracture or have BMD values consistent with osteoporosis.

Keywords: DEXA; anabolic agents; antiresorptive agents; bone mineral density; osteoporosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None.

References

    1. Dunnewind T, Dvortsin E P, Smeets H M et al.Economic consequences and potentially preventable costs related to osteoporosis in the Netherlands. Value Health. 2017;20(06):762–768. - PubMed
    1. Ensrud K E, Crandall C J. Osteoporosis. Ann Intern Med. 2017;167(03):ITC17–ITC32. - PubMed
    1. Fukumoto S, Matsumoto T. Recent advances in the management of osteoporosis. F1000 Res. 2017;6:625. - PMC - PubMed
    1. Qaseem A, Forciea M A, McLean R M, Denberg T D; Clinical Guidelines Committee of the American College of Physicians.Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians Ann Intern Med 201716611818–839. - PubMed
    1. Kuo T R, Chen C H. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18. - PMC - PubMed